Objective: To evaluate the prevalence of b 3 -adrenergic receptor (ADRB3) Trp64Arg polymorphism and its relationship with the metabolic syndrome in severe obesity. Design: Cross-sectional outpatients study. Patients and methods: In 265 (100 men) severely obese non-diabetic subjects and 78 (25 men) healthy volunteers, genomic DNA was isolated from peripheral leukocytes. In obese patients, plasma concentrations of leptin, lipids, glucose and insulin, the homeostasis model assessment index and blood pressure have been measured. The Trp64Arg mutation was identified with the real-time TaqMan method. Results: Neither genotype distribution nor allele frequency differed between the two groups. The metabolic syndrome prevalence was 59% in obese subjects, and was higher in men than in women (65 vs 55%: P ¼ 0.03). The body mass index (BMI) was related to age tertiles (b ¼ 0.08; Po0.001; multiple linear regression) in Trp64Arg-positive obese subjects. Conclusion: We confirm the high prevalence of the metabolic syndrome among severely obese subjects. ADRB3 polymorphism was significantly related to insulin resistance only in obese male subjects. Moreover, increased BMI was related to age in obese subjects with the ADRB3 polymorphism.
Introduction
Overeating and physical inactivity, combined with genetic predisposition, are the main causes of obesity in humans. Efforts to identify obesity genes have traditionally focused on white and brown adipose tissues (Arner, 2000) , which play a crucial role in regulating energy storage and fuel mobilization in mammals. The ADRB3 gene is involved in regulating thermogenesis and lipolysis (Arch and Kaumann, 1993) . In fact, its stimulation by b-adrenergic agonists activates adenylate cyclase, which, in turn, increases intracellular concentrations of cyclic AMP thereby causing increased lipolysis in white adipose tissue and heat production in brown adipose tissue (Zaagsma and Nahorski, 1990; Lofontan and Berlan, 1993; Katzmarzyk et al., 1999) .
In humans ADRB3 is highly expressed in visceral fat (Krief et al., 1993) and is responsible for increases in lipolysis and the delivery of free fatty acid into the portal vein (Lönnqvist et al., 1995) . A mutation in codon 64 of ADRB3 leads to replacement of tryptophan by arginine (Trp64Arg), which is located in the first intracellular loop of ADRB3, and might affect binding to noradrenalin and coupling to G proteins in adipose cells . Therefore the Trp64Arg mutation appears to affect at least some of the receptor's functions in vivo (Candelore et al., 1996; Pietri-Rouxel et al., 1997; Snitker and Odeleye, 1997) and in vitro (Hoffstedt et al., 1999) , which would account for decreased lipolysis in white adipose tissue (Katzmarzyk et al., 1999) .
The Arg64 variant of the ADRB3 gene has been associated with an earlier onset of type II diabetes mellitus and a decreased acute insulin response to glucose (Walston et al., 2000) . The pancreas is a major site of ADRB3 gene expression, and cell transfection with Arg64 was associated with a decrease in glucose-dependent insulin secretion (Perfetti et al., 2001) . ADRB3 gene is therefore involved in several metabolic pathways which could be directly or indirectly linked to energy balance and body weight regulation. However, the association between the Trp64Arg ADRB3 polymorphism and obesity is still controversial, in particular, in Caucasian populations. About half the studies identified an association between the mutation and excess body fat mass (Kadowaki et al., 1995; Walston et al., 1995; Widen et al., 1995; Yoshida et al., 1995; Luke et al., 1997) , whereas the other half did not (Awata and Katayama, 1996; Gagnon et al., 1996; Ueda et al., 1997; Shiwaku et al., 1998) . The Trp64Arg mutation was found to predict a greater tendency for abdominal adiposity and high blood pressure with advancing age in a large working population of males from South Italy (Strazzullo et al., 2001) . It seems to have a weak effect on actual body mass index (BMI); indeed, only a barely statistically significant difference emerged from metaanalyses (Allison et al., 1998; Fujisawa et al., 1998; Kurokawa et al., 2001) . These divergent results may be, at least in part, due to population sampling variations, differences in ethnicity, sex, age and degree of excess body fat.
Morbid obesity (BMI 440 kg/m 2 ), which is increasing in adults and children (Flegal et al., 2002) , has a strong genetic component (Price et al., 1990; Adams et al., 1993) . Consequently, there patients may represent a good sample in which to evaluate the role of ADRB3 polymorphisms in obesity predisposition.
Of the two studies that looked for a link between the ADRB3 Trp64Arg polymorphism and severe obesity, one identified an association (Clement et al., 1995) and the other did not (Oksanen et al., 1996) . Furthermore, the association between the metabolic syndrome (Grundy et al., 2005) and the ADRB3 polymorphism has not been evaluated in severely obese subjects.
We have investigated the association of the Trp64Arg polymorphism with obesity-related phenotypes, in particular, with the metabolic syndrome in a homogenous population of severely obese (BMI440 kg/m 2 ) subjects from South Italy. Our aim was to determine the prevalence of the Trp64Arg mutation in severe obesity, and to establish whether this mutation is related with the metabolic syndrome.
Subjects and methods

Subjects
The study population consisted of 265 (100 men, 165 women) severely obese non-diabetic subjects (type III obesity) recruited from the outpatient obesity clinic of the Department of Internal Medicine, 'Federico II' University Hospital in Naples. All subjects had normal liver, kidney and thyroid functions, and none had a history of excessive alcohol intake. No subject was taking antihypertensive drugs or substances known to affect basal metabolic rate, or glucose or lipid metabolism. We evaluated the frequency of the ADRB3 Trp64Arg polymorphism in the obese subjects and in 78 (25 men 53 women) healthy normal weight volunteers recruited from blood donors living in the same area of South Italy. Obese subjects and controls gave their informed consent to the study, which was approved by the Ethics Committee of our University Hospital.
Anthropometric and metabolic measurements
Weight and height were measured and the BMI calculated as the body weight (kg) divided by the squared height (m 2 ). Systolic and diastolic blood pressures were measured after the subject had rested for 5 min in a sitting position. After a 10-h overnight fast, 20 ml of blood were collected and immediately centrifuged at room temperature. Plasma glucose was measured by the hexokinase method adapted for an autoanalyzer (Hitachi Modular, Tokyo, Japan). Total cholesterol, triglycerides and high-density lipoprotein (HDL) cholesterol were determined by standard enzymatic methods (Hitachi Modular). Low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald formula (Friedewald et al., 1972) . Serum insulin was measured by the chemiluminescence method (Immulight 2000; Medical System, Genova, Italy). Serum leptin concentrations were measured in duplicate in obese and control individuals with a human leptin enzyme immunoassay (Linco Research, St. Charles, MO, USA). Insulin resistance was estimated according to the homeostasis model assessment (HOMA-IR) method from fasting glucose and insulin concentrations, according to the formula: insulin (mU/ml) Â glucose (mmol/l)/22.5 (Matthews et al., 1985) . Metabolic syndrome was diagnosed considering the combination of three out of five risk factors according to AHA criteria (Grundy et al., 2005) .
Genotyping
Genomic DNA was extracted from peripheral leukocytes with a widely used procedure (Nucleon BAAC-2, Amersham, Little Chalfont, Buckinghamshire, UK). The ADRB3 Trp64Arg polymorphism was identified by the real-time TaqMan method (Applied Biosystems, Foster City, CA, USA) and two fluorescent probes: one specific for the wild-type allele, labeled with the VIC fluorescent reporter dye, and the other complementary to the mutant allele, labeled with the FAM marker. We used the Primer Express program to design the polymerase chain reaction (PCR) primers forward 5 0 -GCAACCTGCTGGTCATCGT-3 0 , reverse 5 0 -GTTGGTCATGGT CTGGAGTCT-3 0 ; MGB TaqMan probes VIC-CATCGCCTGGA CTC-Q-MGB and FAM-ATCGCCCGGACTC-Q-MGB where MGB is the minor groove binder, a molecule that stabilizes the duplex DNA probe thereby increasing the ability of the hybridization probe to discriminate the single-nucleotide polymorphism). Reaction mixtures were assembled in a 384-well plate using a Biomek 2000 Workstation (Beckman Instruments, Fullerton, CA, USA). Each consisted of: 40 ng of genomic DNA, 36 nM primers, 8 nM probes and 2.5 ml TaqMan Universal Master Mix (Applied Biosystems) in a total reaction of 5 ml. Negative and positive controls (i.e. no DNA, homozygote and heterozygote samples for the Trp64Arg previously typed by sequence analysis on ABI Prism 3100 Genetic Analyzer, Applied Biosystems) were also tested for internal quality control. Real-time PCR was carried out on an ABI Prism 7900 HT instrument with the Sequence Detection System (SDS 2.1) and the SDS Enterprise Database (Applied Biosystems). The amplification protocol consisted of: 501C for 2 min; 951C for 10 min; 921C for 15 s, 601C for 1 min for 40 cycles; final extension at 601C for 1 min; final soak at 251C. The genotypes were determined without prior knowledge of the subjects' status (Afonina et al., 1997; Livak, 1999; Kutyavin et al., 2000) . 
Statistics
Results
The mean age of obese subjects was 32. 6711.6 years and their mean BMI was 48.277.5 kg/m 2 . Table 1 lists genotype distributions and allele frequencies of the ADRB3 Trp64Arg polymorphism in obese patients and controls. There were no homozygotes. Neither genotype distribution nor allele frequency differed between obese subjects and controls or between men and women. Genotype frequencies were in accordance with Hardy-Weinberg expectations in the obese (P ¼ 0.99) and control (P ¼ 0.99) groups.
At multiple linear regression analysis, BMI was significantly related to age (b ¼ 0.08; Po0.001) only in patients carrying the Trp64Arg mutation. The prevalence of the metabolic syndrome was 59% in the group of obese subjects, and was significantly higher in males than in females (65 vs 55%: P ¼ 0.03). Table 2 shows the results of the multiple linear regression analysis of the association between the metabolic variables measured and ADRB3 genotype in patients. LDL cholesterol was slightly higher in the wildtype group approaching statistical significance (P ¼ 0.06); no significant differences were observed between wild-type and carriers. Figure 1 shows the results of monovariate (panels a-c) and multivariate (d) analyses of the effect of the gendergenotype interaction on insulin resistance and related dyslipidemia. Only in the patients with the Trp64Arg Metabolic syndrome and ADRB3 gene polymorphism R Bracale et al Figure 1 Monovariate (a-c) and multivariate (d) analysis of the effect of the gender-genotype interaction on insulin resistance-related dyslipidemia. In males with severe obesity (n ¼ 100: wild type, n ¼ 96; heterozygote, n ¼ 4), concentrations of insulin (Po0.001) and triglyceride (Po0.05) were significantly higher and HDL cholesterol significantly lower (Po0.001) than in obese females (n ¼ 165: wild type, n ¼ 156; heterozygote, n ¼ 9) (a-c). The differences were more marked in Trp64Arg-positive subjects; and the gender-genotype interaction was statistically significant (Po0.05) for insulin. Principal component analysis of the three variables was calculated using a component that accounts for 51% of variance. The principal component score, which reflects insulin resistance, was higher in obese males Trp64Arg carriers (Po0.001), with a significant gender-genotype interaction (Po0.05) (Figure 1d ).
Metabolic syndrome and ADRB3 gene polymorphism R Bracale et al genotype, insulin and triglyceride levels were significantly higher (Po0.001 and Po0.05, respectively), and HDL cholesterol was significantly lower (Po0.001) in men than in women (panels a-c). The interaction between gender and genotype was statistically significant only for insulin (P ¼ 0.037). The principal component analysis of the three variables (insulin, triglycerides and HDL) was calculated using a component that accounts for 51% of variance. The principal component score, which reflects insulin resistance, was significantly higher in obese males Trp64Arg carriers (Po0.001), with a significant gender-genotype interaction (Po0.026) (Figure 1d ).
Discussion
This study was carried out in a population of severely obese patients, where a strong polygenic component is expected (Price et al., 1990; Adams et al., 1993) thus representing a target population for genetic studies in human obesity (Clement et al., 1995; Oksanen et al., 1996) . The prevalence of the ADRB3 Trp64Arg polymorphism in our obese subjects did not differ from that in the control subjects or from the prevalence already identified in adult male employers of the Olivetti plant in South Italy (Strazzullo et al., 2001) . In the Québec Family Study cohort (1268 individuals from French-Canadian families) the allelic frequency for the carriers and non-carriers of Trp64Arg were 0.92 and 0.08, respectively (Gagnon et al., 1996) . In a subsample of obese women (37-60 years old; BMI430 kg/m 2 ) of this Canadian population, the allelic frequency of the Arg64 was 0.07 versus 0.04 in controls (Gagnon et al., 1996) . Furthermore, no significant difference in the frequency of the Trp64Arg polymorphism was observed between obese and lean subjects in German and Finnish studies (Oksanen et al., 1996; Evans et al., 2000) . In particular, the frequency of the Arg64 allele did not differ in Finnish subjects with severe obesity (BMIX40 kg/m 2 ; 9.1%) and in lean healthy control subjects (8.9%) (Oksanen et al., 1996) .
In our study, there were no Arg64Arg homozygote in either the obese or the control group, and heterozygote were B5% in both groups in accordance to the literature.
Our data show that Trp64Arg polymorphism is significantly related to weight gain with age thus confirming the results of the Olivetti study carried out in a male working population from the same geographical area (Strazzullo et al., 2001) . Overall, these observations are in line with the finding that low fat oxidation over time predicts a mild, progressive increase of body fat (Seidell et al., 1992; Astrup et al., 1997; Marra et al., 2004) . It is therefore conceivable that impaired ADRB3 activity may promote body weight gain by reducing lipolysis in adipose tissue and possibly by reducing thermogenesis, that is reduced as a consequence of aging. Indeed an impairment with age of adrenergic-related thermogenesis could be further increased by ADRB3 polymorphism (Seals and Bell, 2004) .
More convincing association between ADRB3 polymorphism and BMI has been reported in Asian population where the prevalence of ADRB3 polymorphism is higher than in Caucasian population (Fujisawa et al., 1998; Thomas et al., 2000; Kurokawa et al., 2001) .
In our severely obese subjects, the ADRB3 polymorphism was not significantly associated with the metabolic syndrome, apart from insulin resistance related dyslipidemia in males. Cross-sectional analyses based on data from the Québec Family Study did not reveal any difference in glucose, insulin and resting blood pressure values between carriers versus non-carriers of the Trp64Arg mutation (Gagnon et al., 1996) . On the other hand, in Japanese subjects it has been reported that the ADRB3 polymorphism has been associated with insulin resistance but not with dyslipidemia (Kadowaki et al., 1995) .
The data about the effect of the ADRB3 mutation on serum triglycerides appear not conclusive. In three studies, the Arg64 allele was unrelated to the plasma lipid profile (Widen et al., 1995; Moriarty et al., 1997; Ukkola et al., 2000) . Another study on the mutation carried out in young healthy Danes reported an increase in triglycerides and LDL cholesterol in Arg64 homozygotes (Urhammer et al., 1996) . In a Spanish study, ADRB3 gene variants were significantly related to triglyceride and total cholesterol concentrations in men (Corella et al., 2001 ).
In conclusion in our population of severely obese patients the prevalence of the ADRB3 polymorphism did not differ from that of the control group. On the other hand, the polymorphism was associated in obese patients with a significantly higher age-related BMI. The prevalence of MS was as expected, quite high in our obese subjects and irrespective of the ADRB3 gene polymorphism. However, insulin resistance was found higher in obese males carrying the ADRB3 mutation. Further data from prospective studies are required to clarify the relationship between aging and increased BMI as related to ADRB3 polymorphism as well as other thermogenesis-related genes.
